Table 1. Clinical characteristics of patients who accepted regorafenib.
| Variable | Sorafenib group | Lenvatinib group | Total (%) | P |
|---|---|---|---|---|
| Age, years | 58.5 (33.0–71.0) | 50.0 (33.0–75.0) | 54.5 (33.0–75.0) | 0.033 |
| Sex | ||||
| Male | 20 (90.9) | 25 (89.3) | 45 (90.0) | 0.849 |
| Female | 2 (9.1) | 3 (10.7) | 5 (10.0) | |
| ECOG performance status | ||||
| 0 | 8 (36.4) | 14 (50.0) | 22 (44.0) | 0.371 |
| 1 | 13 (59.1) | 14 (50.0) | 27 (54.0) | |
| 2 | 1 (4.5) | 0 (0) | 1 (2.0) | |
| TBIL, μmol/L | 17.3 (6.7–60.8) | 14.6 (4.0–34.4) | 15.9 (4.0–60.8) | 0.018 |
| ALT, U/L | 27.0 (12.0–189.0) | 34.0 (13.0–71.0) | 31.5 (12.0–189.0) | 0.646 |
| AST, U/L | 34.0 (16.0–200.0) | 35.5 (16.0–111.0) | 34.5 (16.0–200.0) | 0.914 |
| ALB, g/L | 38.9 (8.7–48.2) | 40.5 (9.5–50.6) | 40.4 (8.7–50.6) | 0.338 |
| Pre-ALB, mg/L | 157.0 (42.0–254.0) | 177.5 (64.0–334.0) | 165 (42.0–334.0) | 0.107 |
| PT, seconds | 11.9 (10.0–13.7) | 11.7 (10.2–13.3) | 11.9 (10.0–13.7) | 0.145 |
| PLT, 109/L | 125.0 (33.0–222.0) | 118.0 (61.0–220) | 118.0 (33.0–222.0) | 0.538 |
| NLR | 3.1 (0.5–14.8) | 3.2 (0.9–7.9) | 3.2 (0.5–14.8) | 0.369 |
| PLR | 8.15 (5.8–23.2) | 5.5 (2.1–16.9) | 5.5 (1.8–23.2) | 0.845 |
| PNI | 39.4 (9.4–49.2) | 41.0 (9.9–51.4) | 40.9 (9.4–51.4) | 0.348 |
| HBV-DNA level, IU/mL | ||||
| <2,000 | 16 (72.7) | 22 (78.6) | 38 (57.1) | 0.631 |
| ≥2,000 | 6 (27.3) | 6 (21.4) | 12 (42.9) | |
| HbsAg | ||||
| Negative | 1 (4.5) | 4 (14.3) | 5 (10.0) | 0.254 |
| Positive | 21 (95.5) | 24 (85.7) | 45 (90.0) | |
| Liver cirrhosis a | ||||
| N | 2 (9.1) | 7 (25.0) | 9 (18.0) | 0.146 |
| Y | 20 (90.9) | 21 (75.0) | 41 (82.0) | |
| AFP, μg/L | 75.7 (1.6–108571.0) | 176.5 (1.2–162793.0) | 83.8 (1.2–162791.8) | 0.883 |
| AFP, μg/L | ||||
| <400 | 13 (59.1) | 16 (57.1) | 29 (58.0) | 0.890 |
| ≥400 | 9 (40.1) | 12 (42.9) | 21 (42.0) | |
| CEA, ng/mL | 2.8 (1.0–44.4) | 2.6 (0.8–6.3) | 2.7 (0.8–44.4) | 0.322 |
| CA 199, U/mL | 16.4 (2.0–138.0) | 15.3 (2.0–216.0) | 15.7 (2.0–216.0) | 0.272 |
| PIVKA-II, μg/L | 1868.5 (24.0–912229.0) | 2025.5 (20.0–125947.0) | 1929 (20.0–912229.0) | 0.777 |
| BCLC stage | ||||
| A | 2 (9.1) | 2 (7.1) | 4 (8.0) | 0.916 |
| B | 11 (50.0) | 8 (46.4) | 19 (38.0) | |
| C | 9 (40.9) | 13 (46.4) | 22 (44.0) | |
| Tumor diameter, cm a | ||||
| <5 | 8 (36.4) | 9 (32.1) | 17 (34.0) | 0.754 |
| ≥5 | 14 (63.6) | 19 (67.9) | 33 (66.0) | |
| Number of tumors a | ||||
| Single | 2 (9.1) | 5 (17.9) | 7 (14.0) | 0.375 |
| Multiple | 20 (90.9) | 23 (82.1) | 43 (86.0) | |
| Vascular invasion a | ||||
| N | 14 (63.6) | 18 (64.3) | 32 (64.0) | 0.962 |
| Y | 8 (36.4) | 10 (35.7) | 18 (36.0) | |
| Extrahepatic metastasis a | ||||
| N | 17 (77.3) | 23 (82.1) | 40 (80.0) | 0.669 |
| Y | 5 (22.7) | 5 (17.9) | 10 (20.0) | |
a, Based on pre-treatment imaging studies. Data were presented as number (%) or median (IQR). ECOG, Eastern Cooperative Oncology Group; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; pre-ALB, prealbumin; PT, prothrombin time; PLT, platelet count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; HBV, hepatitis B virus; AFP, alpha fetoprotein; CEA, carcinoembryonic antigen; CA 199, carbohydrate antigen 199; PIVKA-II, protein induced by vitamin K absence or antagonist-II; BCLC, Barcelona clinic liver cancer; N, no; Y, yes.